Roivant Sciences Ltd.ROIV
What Roivant Sciences Ltd. does.
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Note: All product candidates in our current pipeline are investigational and subject to health authority approval. The “Phase” for a specific product candidate referenced above reflects both ongoing clinical trials and expected upcoming trials.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Net income | -$809.2M | -$845.3M | -$1.0B | $4.3B | -$172.0M | -$299.8M |
| Free cash flow | -$557.9M | -$695.2M | -$856.1M | -$766.6M | -$844.0M | -$758.6M |
More on ROIV.
- Roivant Sciences Ltd. summary
- Roivant Sciences Ltd. financial statements
- Roivant Sciences Ltd. key metrics
- Roivant Sciences Ltd. health scores and style box
- Roivant Sciences Ltd. earnings
- Roivant Sciences Ltd. dividends
- Roivant Sciences Ltd. valuation
- Roivant Sciences Ltd. ownership and insiders
- Roivant Sciences Ltd. peers
Figures from Roivant Sciences Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.